Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q2 2019 Earnings Presentation
11 slides from Anika Therapeutics's earnings presentation, Jul 24, 2019
Slide 1: Second Quarter 2019 Earnings Call Presentation
Second Quarter 2019 Earnings Call Presentation July 24, 2019 Nasdaq: ANIK
Slide 2: Safe Harbor Statements
Safe Harbor Statements Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: CINGAL U.S. Development Update
CINGAL U.S. Development Update Next Generation Osteoarthritis Therapy Completed extensive analyses and made the decision to move forward with efforts to bring CINGAL to the U.S. market Initiating a pilot clinical study designed to increase our probability of success in a Phase III trial and generate
Slide 4: Expanding Commercial and Business Development Capabilities
Expanding Commercial and Business Development Capabilities Strengthening Foundation for Long-Term Value Creation U.S. Commercial: Onboarded 3 highly-skilled Regional Sales Directors under VP of U.S. Sales; Provide feet on the ground ahead of upcoming launch of our bone repair therapy International C
Slide 5: Hybrid Commercial Model Update
Hybrid Commercial Model Update Enhancing Visibility and Control to Drive Rapid Growth Onboarded 3 regional sales directors in the U.S. Continuing to evaluate a number of potential regional and national commercial partners with established orthopedic surgical sales forces Expect to launch bone repair
Slide 6: Growing Portfolio of Regenerative Treatments
Growing Portfolio of Regenerative Treatments Bone Repair and Rotator Cuff Therapies BONE REPAIR THERAPY Commercial soft launch expected in Q3 2019 Plan to utilize hybrid commercial model Recently showcased at American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting and International S
Slide 7: HYALOFAST Phase III Clinical Trial
HYALOFAST Phase III Clinical Trial The Future of Cartilage Regeneration Amended Phase III trial protocol; Expanded number of sites from 40 to 60, plan to add new OUS sites in 2H 2019 with potential to accelerate enrollment; Augmented the enrollment criteria to target our optimal patient population R
Slide 8: Q2 2019 Financial Highlights
Q2 2019 Financial Highlights Top and Bottom Line Performance Exceeds Expectations Total Revenue Diluted EPS Product Gross Margin (Millions) 6% $30.5 $30.4 $0.68 $0.67 78% Q2 Adjusted EBITDA1 73% $141M Cash & Investments as of 6/30/2019; No debt Q2 2018 Q2 2019 Q2 2018 Q2 2019 Q2 2018 Q2 2019 Interna
Slide 9: 2019 Guidance Update
2019 Guidance Update Raised Full Year 2019 Revenue and Adjusted EBITDA Guidance Prior Guidance Updated Guidance Total ~3% - 6% below FY 2018 ~1% - 4% above FY 2018 Revenue Operating High $70 million to High $70 million range Expenses $80 million Net Income Mid-teen to ~$20 million Mid-$20 million ra
Slide 10: Near and Long-Term Growth Drivers
Near and Long-Term Growth Drivers Propelling Transformation into a Global Commercial Company Launch of bone repair and rotator cuff repair therapies under hybrid commercial model - Led by VP of U.S. Sales International expansion of Orthobiologics franchise - Led by VP of International Sales Advancin
Slide 11: Q&A
Q&A Second Quarter 2019 Earnings Call Presentation July 24, 2019